EUVIMEDEUVIMED entdecken
Open Access

Clinical features, diagnosis, and outcome of anaplastic lymphoma kinase tyrosine kinase inhibitors associated interstitial lung disease.

Zhaoquan Wu, Wei Sun, Chunjiang Wang

Sarcoidosis vasculitis and diffuse lung diseases · 22.06.2026 · 43 (2) · 18699-18699

DOI: 10.36141/svdld.2026.18699 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Sarcoidosis vasculitis and diffuse lung diseases, erschienen am 22.06.2026. Verfasst von Zhaoquan Wu und 2 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Changsha Medical University, Changsha, Hunan, China; Hunan Provincial Key Laboratory of the Research and Development of Novel Ph…. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To investigate the clinical features of anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI) -associated interstitial lung disease (ILD), and to provide a reference for the rational use of ALK TKI.

Methods

Cases of ALK TKI-associated ILD before December 31, 2025 were collected by searching the database and clinical data were collected for retrospective analysis.

Result

Fifty patients were included, with a median age of 54.5 years (range 33, 86). The median time of ILD occurrence was 50 days (range 2, 630). Dyspnea (56.0%), hypoxemia (38.0%), cough (36.0%) and fever (26.0%) were the main clinical symptoms, and there may also be no symptoms. Computed tomography mainly showed ground-glass opacities (98.0%). After the patients discontinued ALK-TKI and received systemic steroid treatment, 90.0% of the patients had symptom relief and improved imaging, and 10.0% of the patients died.

Conclusion

ILD is a rare and fatal adverse event of ALK-TKI. The possibility of ILD should be considered if dyspnea, hypoxemia, and cough occur during ALK-TKI use. After ILD recovery, patients could switch to the same ALK-TKI or another ALK-TKI under the protection of glucocorticoid.

Schlagwörter

anaplastic lymphoma kinaseALK inhibitorsinterstitial lung diseasedrug-induced lung injuryadverse drug reactionsground-glass opacitieshypoxemiadyspneacorticosteroid therapytreatment discontinuation

Autor:innen und Institutionen

  • College of Pharmacy, Changsha Medical University, Changsha, Hunan, China; Hunan Provincial Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, Changsha Medical University, Changsha, Huna…
  • Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.

Zitieren

APA

Wu, Z., Sun, W., & Wang, C. (2026). Clinical features, diagnosis, and outcome of anaplastic lymphoma kinase tyrosine kinase inhibitors associated interstitial lung disease. Sarcoidosis vasculitis and diffuse lung diseases, 43(2), 18699-18699. https://doi.org/10.36141/svdld.2026.18699

Vancouver

Wu Z, Sun W, Wang C. Clinical features, diagnosis, and outcome of anaplastic lymphoma kinase tyrosine kinase inhibitors associated interstitial lung disease. Sarcoidosis vasculitis and diffuse lung diseases. 2026;43(2):18699-18699. doi:10.36141/svdld.2026.18699

BibTeX
@article{Wu2026,
  author = {Wu, Zhaoquan and Sun, Wei and Wang, Chunjiang},
  title = {Clinical features, diagnosis, and outcome of anaplastic lymphoma kinase tyrosine kinase inhibitors associated interstitial lung disease},
  journal = {Sarcoidosis vasculitis and diffuse lung diseases},
  year = {2026},
  volume = {43},
  number = {2},
  pages = {18699--18699},
  doi = {10.36141/svdld.2026.18699}
}
Kostenlos starten →